keyword
MENU ▼
Read by QxMD icon Read
search

belimumab

keyword
https://www.readbyqxmd.com/read/29426575/systematic-review-and-meta-analysis-of-steroid-sparing-effect-of-biologic-agents-in-randomized-placebo-controlled-phase-3-trials-for-systemic-lupus-erythematosus
#1
REVIEW
Shereen Oon, Molla Huq, Timothy Godfrey, Mandana Nikpour
OBJECTIVES: To systematically review, and conduct a meta-analysis of steroid-sparing effect in, phase 3 randomized, placebo-controlled trials of biologic therapies for systemic lupus erythematosus (SLE). METHODS: Studies were identified by searching Medline (via Pubmed), EMBASE, CINAHL and SCOPUS databases, the Cochrane library, and clinicaltrials.gov. Adult human studies published in English in the last ten years (until 18/04/2017) were included. A random-effects meta-analysis comparing a common corticosteroid-reduction endpoint in the trials of rituximab, belimumab, tabalumab and epratuzumab in SLE, was conducted...
January 6, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29409143/long-term-safety-and-efficacy-of-belimumab-in-patients-with-systemic-lupus-erythematosus-a-continuation-of-the-phase-3-united-states-bliss-76-trial
#2
Richard A Furie, Daniel J Wallace, Cynthia Aranow, James Fettiplace, Barbara Wilson, Prafull Mistry, David A Roth, D Gordon
OBJECTIVE: This US multicenter continuation study (GSK Study BEL112233; NCT00724867) assessed long-term safety and efficacy of belimumab in patients with SLE who completed BLISS-76 (NCT00410384). METHODS: Patients continued to receive the same belimumab dose plus standard of care; patients previously receiving placebo received belimumab 10 mg/kg. Primary outcome measures included long-term safety (AE frequency and damage assessed by Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI] evaluated every 48 weeks [study year])...
February 6, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29403543/when-myasthenia-gravis-is-deemed-refractory-clinical-signposts-and-treatment-strategies
#3
REVIEW
Renato Mantegazza, Carlo Antozzi
The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half century, including substantial reductions in mortality and morbidity. However, approximately 10% of patients fails to respond adequately to current therapies and are considered treatment refractory, or treatment intolerant, and up to 80% have disease that fails to achieve complete stable remission. Although patients with autoantibodies to muscle-specific tyrosine kinase (anti-MuSK positive) are more likely to become treatment refractory than those with autoantibodies to the acetylcholine receptor (anti-AChR positive), each of these serotypes is substantially represented in the refractory MG population...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29396833/belimumab-a-review-in-systemic-lupus-erythematosus
#4
Hannah A Blair, Sean T Duggan
Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE). Belimumab is approved in the EU, the USA and other countries as add-on therapy in adult patients with active, autoantibody-positive SLE despite standard therapy. In phase III trials, treatment with IV or SC belimumab plus standard therapy was effective in terms of reducing overall disease activity and reducing the incidence and severity of flares, without worsening of patients' overall condition or the development of significant disease activity in new organ systems...
February 2, 2018: Drugs
https://www.readbyqxmd.com/read/29381841/epratuzumab-reveille-or-requiem-teachable-moments-for-lupus-and-sjogren-s-clinical-trials
#5
EDITORIAL
Daniel J Wallace
The story of how anti TNFs went from bench to bedside in 5 years is an inspirational, satisfying narrative that changed the lives of millions of patients suffering from rheumatoid arthritis and the spondyloarthropathies. Rituximab received approval for ANCA positive vasculitis on the basis of a single study with fewer than 200 subjects. Unfortunately, attempts to obtain approval for drugs for systemic lupus erythematosus (SLE) has been a 10 billion dollar failed effort that yielded only belimumab, and has been disappointing for Sjogren's syndrome...
January 30, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29336179/belimumab-and-antipneumococcal-vaccination-in-patients-with-systemic-lupus-erythematosus
#6
Tudor Azoicai, Sabina Antoniu, Irina Draga Caruntu, Doina Azoicai, Ileana Antohe, Cristina Gavrilovici
In systemic lupus erythematosus (SLE), flares can be caused by infections. In particular, Streptococcus pneumoniae infection can be severe or even potentially lethal in absence of previous immunization or in case of 'aggressive' systemic antibiotic therapy. Immunization efficacy, however, can be reduced in such patients with the use of the various immunosuppressive therapeutic regimens. In particular, the use of novel monoclonal antibodies against B lymphocytes raises concerns over the potential interference with antipneumococcal vaccination...
January 22, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29295825/a-pivotal-phase-iii-randomised-placebo-controlled-study-of-belimumab-in-patients-with-systemic-lupus-erythematosus-located-in-china-japan-and-south-korea
#7
Fengchun Zhang, Sang-Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David A Roth, Jie Zheng, Yoshiya Tanaka
BACKGROUND: Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). METHODS: This phase III, multicentre, randomised, double-blind, placebo-controlled study (BEL113750; NCT01345253) was conducted in 49 centres across China, Japan and South Korea (May 2011-September 2015). Patients with SLE were randomised 2:1 to intravenous belimumab 10 mg/kg or placebo, plus SoC, every 4 weeks until Week 48...
January 2, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29180126/belimumab-in-the-treatment-of-systemic-lupus-erythematous-an-evidence-based-review-of-its-place-in-therapy
#8
REVIEW
Frederico Marcondes, Morton Scheinberg
INTRODUCTION: Systemic lupus erythematous is an autoimmune disease with diverse clinical features and has its development associated with a complexity of genetic, hormonal and environmental factors and the development of autoantibodies. Identification of new treatments is currently an area of intense investigation. Belimumab is the first biologic approved for the treatment of the disease inhibiting the excessive B cell activity observed in these patients and consequently reduction of autoantibodies...
November 24, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29113694/-lupus-erythematosus-treatment-with-belimumab-in-daily-practice-retrospective-study-of-15-patients
#9
E Garval, J-L Pennaforte, R Jaussaud, A Servettaz, P Bernard, Z Reguiai
BACKGROUND: Belimumab (an anti-BLyS monoclonal antibody) was recently approved for the treatment of systemic lupus erythematosus (SLE). The aim of the study was to describe efficacy and safety of the drug as well as its impact on serologic parameters and the role of long-term systemic sparing of treatment in clinical practice in LE. PATIENTS AND METHODS: We conducted a retrospective study at Reims University Hospital between 2012 and 2016 including consecutive patients with LE treated with belimumab...
November 4, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29101479/b-cell-based-treatments-in-sle-past-experience-and-current-directions
#10
REVIEW
Stamatis-Nick C Liossis, Chrysanthi Staveri
PURPOSE OF REVIEW: B cells have been targeted recently by novel therapeutic approaches in patients with SLE. In this review, we discuss recent data that have emerged on this issue placing special emphasis in studies published during the last 5 years. RECENT FINDINGS: Despite the negative results stemming from double-blind placebo-controlled studies, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory lupus, with promising results...
November 4, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29073351/belimumab-for-the-treatment-of-early-diffuse-systemic-sclerosis-results-of-a-randomized-double-blind-placebo-controlled-pilot-trial
#11
Jessica K Gordon, Viktor Martyanov, Jennifer M Franks, Elana J Bernstein, Jackie Szymonifka, Cynthia Magro, Horatio F Wildman, Tammara A Wood, Michael L Whitfield, Robert F Spiera
OBJECTIVE: To assess the safety and efficacy of treatment with belimumab in patients with early diffuse cutaneous systemic sclerosis (dcSSc) treated with background mycophenolate mofetil (MMF). METHODS: In this 52-week, investigator-initiated, single-center, double-blind, placebo-controlled, pilot study, 20 patients recently started on MMF were randomized 1:1 to additionally receive belimumab 10 mg/kg intravenously or placebo. We assessed safety, efficacy and differential gene expression (NCT01670565)...
October 26, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29029693/what-can-google-and-wikipedia-can-tell-us-about-a-disease-big-data-trends-analysis-in-systemic-lupus-erythematosus
#12
Savino Sciascia, Massimo Radin
OBJECTIVE: To investigate trends of Internet search volumes linked to Systemic Lupus Erythematosus (SLE), on-going clinical trials and research developments associated to the disease, using Big Data monitoring and data mining. METHODS: We performed a longitudinal analysis based on the large amount of data generated by Google Trends, scientific search tools (SCOPUS, Medline/Pubmed/ClinicalTrails.gov) considering 'SLE', and 'lupus' in a 5-year web-based research. Wikipedia page views were also analysed using WikiTrends and the results were compared with the search volumes generated by Google Trends...
November 2017: International Journal of Medical Informatics
https://www.readbyqxmd.com/read/28992184/immune-complexes-containing-serum-b-cell-activating-factor-and-immunoglobulin-g-correlate-with-disease-activity-in-systemic-lupus-erythematosus
#13
Justa Friebus-Kardash, Leonore Branco, Camillo Ribi, Carlo Chizzolini, Uyen Huynh-Do, Denise Dubler, Pascale Roux-Lombard, Sebastian Dolff, Andreas Kribben, Ute Eisenberger, Marten Trendelenburg
Background: B-cell activating factor belonging to the TNF family (BAFF) is important for the survival of autoreactive B-cells in systemic lupus erythematosus (SLE). However, the association between serum BAFF levels and SLE disease activity is controversial. Independently, autoantibodies targeting BAFF [immunoglobulin G (IgG) anti-BAFF] have also been described in SLE patients and were associated with increased disease activity. The aim of our study was to analyse the relationship between SLE disease manifestations and serum levels of BAFF, IgG anti-BAFF and BAFF-IgG complexes...
August 8, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28963832/-membranous-glomerulonephritis-mgn-ongoing-studies
#14
REVIEW
Gaetano La Manna, Olga Baraldi, Vania Cunia, Valeria Corradetti, Valeria Aiello, Marco Busutti, Lorenzo Gasperoni, Alessandra Spazzoli, Giorgia Comai
The membranous nephropathy (MN) is the major cause of nephrotic syndrome in in the adult, account for 20% of cases with annual incidence is 1 in 100.000. In the past 10 years, the role of podocytes has been identified; environmental triggers in genetically predisposed patients can activate podocytes to exhibit antigenic epitopes (receptor of phospholipase A2, thrombospondin type 1) that become targets of specific autoantibodies with subsequent complement activation. The discovery of this mechanisms has opened new horizons in the therapy of MN and novel drugs are available with more specific mechanism of action...
September 28, 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28956281/patient-evaluation-of-satisfaction-and-outcomes-with-an-autoinjector-for-self-administration-of-subcutaneous-belimumab-in-patients-with-systemic-lupus-erythematosus
#15
Ebony Dashiell-Aje, Gale Harding, Katie Pascoe, Jane DeVries, Pamela Berry, Sulabha Ramachandran
OBJECTIVE: This study assessed patient experiences of using an autoinjector device to self-administer subcutaneous belimumab for the treatment of systemic lupus erythematosus (SLE). Satisfaction, ease and convenience of use, and confidence with the device were assessed, in addition to overall experience with belimumab. METHODS: This cross-sectional study was conducted among patients who completed a phase IIb open-label, multi-dose usability, tolerability, and safety study of subcutaneous belimumab (NCT02124798), in which patients receiving intravenous belimumab or subcutaneous belimumab using a prefilled syringe were switched to eight weekly self-administered doses of subcutaneous belimumab using the autoinjector...
September 27, 2017: Patient
https://www.readbyqxmd.com/read/28935492/clinical-predictors-of-response-and-discontinuation-of-belimumab-in-patients-with-systemic-lupus-erythematosus-in-real-life-setting-results-of-a-large-multicentric-nationwide-study
#16
Luca Iaccarino, Laura Andreoli, Elena Bartoloni Bocci, Alessandra Bortoluzzi, Fulvia Ceccarelli, Fabrizio Conti, Rossella De Angelis, Ginevra De Marchi, Salvatore De Vita, Andrea Di Matteo, Giacomo Emmi, Lorenzo Emmi, Mariele Gatto, Roberto Gerli, Maria Gerosa, Marcello Govoni, Maddalena Larosa, Pier Luigi Meroni, Marta Mosca, Giulia Pazzola, Rossella Reggia, Francesca Saccon, Carlo Salvarani, Chiara Tani, Margherita Zen, Anna Chiara Frigo, Angela Tincani, Andrea Doria
OBJECTIVE: To investigate efficacy, safety and survival of belimumab and to identify predictors of drug response and drug discontinuation in patients with active SLE in clinical practice. PATIENTS AND METHODS: Data of SLE patients, treated with belimumab, from 11 Italian prospective cohorts were analyzed. SLEDAI-2K, anti-dsDNA, C3, C4, prednisone daily dose, DAS-28, 24-h proteinuria, CLASIa (Cutaneous LE Disease Area and Severity Index Activity) were recorded at baseline and every 6 months...
September 18, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28887801/population-pharmacokinetic-and-pharmacodynamic-analysis-of-belimumab-administered-subcutaneously-in-healthy-volunteers-and-patients-with-systemic-lupus-erythematosus
#17
Herbert Struemper, Mita Thapar, David Roth
BACKGROUND: Intravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneous 200-mg weekly administration, which may prove more convenient for patients and improve adherence, is currently under investigation. OBJECTIVE: The objective of this study was to characterize the population pharmacokinetics and exposure-efficacy response of subcutaneous belimumab in a pooled analysis of pharmacokinetic data [phase I: BEL114448 (NCT01583530) and BEL116119 (NCT01516450) in healthy subjects (n = 134); phase III: BEL112341 (NCT01484496) in adults with systemic lupus erythematosus (n = 554)] and pharmacodynamic data [BEL112341 in adults with systemic lupus erythematosus (n = 833)]...
September 8, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28877634/certolizumab-an-anti-tnf-safe-during-pregancy-the-crib-study-results-an-interview-with-professor-xavier-mariette
#18
Xavier Mariette
Professor Xavier Mariette, MD, PhD, has served as the Head of the Rheumatology Department of Bicêtre Hospital, Paris-Sud University since 1999, a role he took following 10 years of practice of clinical immunology. Professor Mariette has initiated a number of clinical research studies on biotherapies in autoimmune diseases. He is the head of the French RATIO (Research Axed on Tolerance of Biotherapy) observatory, collecting specific rare serious adverse events in patients treated with anti-TNF. He initiated the French AIR (Autoimmunity and Rituximab) and ORA (Orencia and Rheumatoid arthritis) registries of patients with autoimmune diseases treated with rituximab and abatacept...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28862513/relationship-between-glucocorticoid-dose-and-adverse-events-in-systemic-lupus-erythematosus-data-from-a-randomized-clinical-trial
#19
S Emamikia, C Gentline, K Chatzidionysiou, L Arnaud, R van Vollenhoven
OBJECTIVE: The aim was to obtain a better understanding of the relationship between exposure to glucocorticoids (GCs) and adverse events (AEs) reported in a randomized controlled trial (RCT) in systemic lupus erythematosus (SLE) patients. METHOD: We used data from the BLISS-76 trial on belimumab. The data were accessed through an agreement under the SHARE mechanism. AEs were grouped according to medical relevance, i.e. based on similarity of symptoms and pathophysiology...
September 1, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28853005/unmet-needs-in-the-pathogenesis-and-treatment-of-systemic-lupus-erythematosus
#20
REVIEW
Jyoti Bakshi, Beatriz Tejera Segura, Christopher Wincup, Anisur Rahman
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a prevalence of approximately 1 in 1000. Over the last 30 years, advances in treatment such as use of corticosteroids and immunosuppressants have improved life expectancy and quality of life for patients with lupus and the key unmet needs have therefore changed. With the reduced mortality from disease activity, development of cardiovascular disease (CVD) has become an increasingly important cause of death in patients with SLE. The increased CVD risk in these patients is partly, but not fully explained by standard risk factors, and abnormalities in the immune response to lipids may play a role...
August 29, 2017: Clinical Reviews in Allergy & Immunology
keyword
keyword
57741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"